广西医疗机构落实国家药品集中带量采购政策的效果分析

曾铮; 巫柳岑; 黄振光; 何文莉; 宓郑成; 谢祥威; 苏思多; 梁桂诚; 廖遥灵; 张宏亮

doi:10.6039/j.issn.1001-0408.2024.05.02

您当前的位置：

首页 >

文章列表页 >

广西医疗机构落实国家药品集中带量采购政策的效果分析

药事管理 | 更新时间：2024-03-08

- 广西医疗机构落实国家药品集中带量采购政策的效果分析
- Analysis of the effects of national centralized drug volume-based procurement policy in public medical institutions of the Guangxi Zhuang Autonomous Region
- 中国药房 2024年35卷第5期页码：518-523
- 作者机构：
  
  1.广西医科大学第一附属医院药学部，南宁　530021
  2.广西壮族自治区卫生健康委药物政策与基本药物制度处，南宁　530000
- 作者简介：
  
  主管药师。研究方向：医院药学。E-mail：173682197@qq.com
  副主任药师，硕士生导师，博士。研究方向：临床药学、循证药学。E-mail：277749097@qq.com
- 基金信息：
  
  广西壮族自治区卫生健康委课题(Z-A20230477)
- DOI：10.6039/j.issn.1001-0408.2024.05.02
  中图分类号： R956;F840.684
- 纸质出版日期：2024-03-15，
  
  收稿日期：2023-07-05，
  
  修回日期：2024-01-04，
扫描看全文
曾铮,巫柳岑,黄振光等.广西医疗机构落实国家药品集中带量采购政策的效果分析 ^Δ[J].中国药房,2024,35(05):518-523.

ZENG Zheng,WU Liucen,HUANG Zhenguang,et al.Analysis of the effects of national centralized drug volume-based procurement policy in public medical institutions of the Guangxi Zhuang Autonomous Region[J].ZHONGGUO YAOFANG,2024,35(05):518-523.
曾铮,巫柳岑,黄振光等.广西医疗机构落实国家药品集中带量采购政策的效果分析 ^Δ[J].中国药房,2024,35(05):518-523. DOI： 10.6039/j.issn.1001-0408.2024.05.02.

ZENG Zheng,WU Liucen,HUANG Zhenguang,et al.Analysis of the effects of national centralized drug volume-based procurement policy in public medical institutions of the Guangxi Zhuang Autonomous Region[J].ZHONGGUO YAOFANG,2024,35(05):518-523. DOI： 10.6039/j.issn.1001-0408.2024.05.02.

摘要

目的

探讨国家药品集中带量采购政策（后文简称“国家集采政策”）在广西壮族自治区的实施效果，为医疗机构后续开展集采药品相关工作提供参考。

方法

选取广西壮族自治区医疗机构国家集采政策实施前后的药品采购数据，以政策目标、利益相关方关注的问题等为导向，引入并研究6个二级指标（如可获得性、可负担性、药品安全性等）、18个三级指标（如约定采购量完成率、负担水平、药占比等）。采用描述性统计方法对国家集采政策实施前后（2019年和2020年）的数据进行差异性、变化趋势等分析。

结果

在可获得性方面：广西壮族自治区医疗机构参与度为92.55%，疾病覆盖率为40.16%，整体约定采购量完成率中值为287.82%，总体配送率为97.20%。在可负担性方面：2019－2022年药品价格总体的降幅为74.80%，人均住院药品费用、门诊药占比、住院药占比降幅依次为17.61%、10.22%、20.10%，除慢性病、抗肿瘤用药外，药品可负担水平均低于1。对医药的影响：2022年药品不良反应事件占比为66.00%，相比执行国家集采政策前增幅为1.29%，广西壮族自治区通过一致性评价的药品共12个品规，前8名的制药企业的市场集中度小于20.00%。对医疗医保的影响：直至2022年基本实现仿制药替代原研药，同类非中选药品使用比约为9.12%，未提出二次换药的人数占63.39%；药品费用支出减少共24.59亿元。

结论

国家集采政策在广西壮族自治区取得了显著的效果，但同时还需重点关注扩大专科病种用药覆盖面、中选药品的临床综合评价、优化待分配量选择方案等问题。

Abstract

OBJECTIVE

To investigate the implementation effects of the national centralized drug volume-based procurement policy （abbreviated as “national centralized procurement policy”） in Guangxi Zhuang Autonomous Region prefecture， and to provide a reference for the future centralized drug procurement work of the medical institution.

METHODS

Drug procurement data before and after policy implementation were included in the study. The six secondary indicators （such as availability， affordability， and drug safety） and eighteen third-level indicators （such as completion rate of agreed purchase volume， affordability level， drug revenue proportion） were introduced， guided by the policy objectives and issues of concern to policy beneficiaries. Descriptive statistics was adopted to analyze the data before and after policy implementation （in 2019 and 2020） in terms of differences and change trends.

RESULTS

In terms of accessibility， the participation rate of medical institutions in Guangxi Zhuang Autonomous Region was 92.55%， the proportion of diseases involved and median completed procurement rate were 40.16%， and 287.82% respectively， and the total centralized delivery rate was 97.20%. In terms of affordability， the total reduction amplitude in drug price was 74.80% from 2019 to 2022； the charge for medicine per capita in hospitalization， the proportion of medicine used for outpatient service and hospitalization， decreased by 17.61%， 10.22%， and 20.10% in order； the burden levels on medical fares for patients were all below 1 in addition to chronic diseases， and anti-tumor drugs. In terms of the impact on medicine， the ratio of adverse drug reaction event cases in 2022 was 66.00%， an increase of 1.29% compared to the previous； since the implementation of the policy， 12 drugs from local pharmaceutical enterprises from Guangxi Zhuang Autonomous Region had passed the consistency evaluation， and the market concentration rate of the top 8 pharmaceutical companies was less than 20.00%. In terms of the impact on healthcare and medical insurance， the public medical institutions achieved generic substitution for originator drugs mostly until 2022； about 9.12% of drugs that were non-centrally purchased in the same category were used； 63.39% of people under investigation did not show a need for a second dressing change； drug expenditure decreased by 2.459 billion yuan.

CONCLUSIONS

The national centralized procurement policy achieves a significant effect in Guangxi Zhuang Autonomous Region. On the other hand， attention should be paid to these suggestions as follows: expanding the category of drugs used in clinic， conducting clinically comprehensive evaluation of selected drugs， and improving reasonable allocation strategy， etc.

关键词

国家药品集中带量采购政策广西壮族自治区实施效果可获得性可负担性药品安全性制药企业影响力

Keywords

Guangxi Zhuang Autonomous Regionimplementation effectaccessibilityaffordabilitydrug safetyinfluence of pharmaceutical producer

references

谢金平，王斌，陈缪丰，等. 常州市第二批国家药品集中采购政策实施效果研究：基于双组间断时间序列分析[J]. 中国卫生政策研究，2022，15（5）：59-66.

XIE J P，WANG B，CHEN M F，et al. Study on the implementation effects of the second batch of national drug centralized procurement policy in Changzhou city：based on two groups interrupted time-series analysis model[J]. Chin J Health Policy，2022，15（5）：59-66.

国务院办公厅.关于印发国家组织药品集中采购和使用试点方案的通知[EB/OL].（2019-01-01）[2023-05-15]. https：//www.gov.cn/gongbao/content/2019/content_5361- 793.htmhttps://www.gov.cn/gongbao/content/2019/content_5361-793.htm.

General Office of the State Council. Notice on issuing the pilot program for centralized procurement and use of national organized drugs[EB/OL]. （2019-01-01）[2023-05-15]. https：//www.gov.cn/gongbao/content/2019/content_5361793.htmhttps://www.gov.cn/gongbao/content/2019/content_5361793.htm.

锁驰. 基于利益相关者的云南省药品集中采购政策效果评价[D]. 昆明：昆明医科大学，2022.

SUO C. Evaluation of the effect of centralized drug procurement policy in Yunnan province based on stakeholders[D]. Kunming：Kunming Medical University，2022.

锁驰，罗碧燕，唐成润，等. 国家组织药品集采执行效果分析：以云南省为例[J]. 中国医疗保险，2023（4）：12-18.

SUO C，LUO B Y，TANG C R，et al. Analysis of the implementation effect of national centralized drug procurement：taking Yunnan province as an example[J]. China Health Insur，2023（4）：12-18.

申芳丽，刘璐，宋沧桑，等. 国家药品集采实施效果与评价：以某三甲医院为例[J]. 中国医疗保险，2021（8）：57-60.

SHEN F L，LIU L，SONG C S，et al. Effect and evaluation of national centralized drug purchase：taking a third class hospital as an example[J]. China Health Insur，2021（8）：57-60.

REGAN T L. Generic entry，price competition，and market segmentation in the prescription drug market[J]. Int J Ind Organ，2008，26（4）：930-948.

李婵，锁驰，徐焦，等. 药品集采效果评价指标体系和模型构建[J]. 中国医疗保险，2022（10）：27-31.

LI C，SUO C，XU J，et al. Construction of effect evaluation index system and model for centralized drug procurement[J]. China Health Insur，2022（10）：27-31.

周婷婷，潘杰. 不同保障水平下罕见病用药可负担性研究：以脊髓性肌萎缩症为例[J]. 中国卫生经济，2022，41（2）：33-38.

ZHOU T T，PAN J. Study on affordability of orphan drugs under different health insurance levels：a case study of spinal muscular atrophy[J]. Chin Health Econ，2022，41（2）：33-38.

SAQIB A，IFTIKHAR S，SARWAR M R. Availability and affordability of biologic versus non-biologic anticancer medicines：a cross-sectional study in Punjab，Pakistan[J]. BMJ Open，2018，8（6）：e019015.

喻娅妮，马永恒，袁蕊蕊，等. 2012－2018年甘肃省药品集中采购情况分析[J]. 中国卫生经济，2020，39（5）：76-78.

YU Y N，MA Y H，YUAN R R，et al. Analysis on the centralized drug procurement in Gansu province from 2012 to 2018[J]. Chin Health Econ，2020，39（5）：76-78.

张慕禹，韩晟，管晓东，等. 抗生素类别药品市场集中度分析[J]. 中国新药杂志，2015，24（13）：1445-1450.

ZHANG M Y，HAN S，GUAN X D，et al. Analysis of market concentration ratio of anti-infective drugs in China[J]. Chin J N Drugs，2015，24（13）：1445-1450.

张宏亮，杨周生，周甘平，等. 广西医疗机构落实药品集中带量采购工作专家共识[J]. 广西医学，2023，45（1）：1-5.

ZHANG H L，YANG Z S，ZHOU G P，et al. Expert consensus on the implementation of centralized procurement of drugs by medical institutions in Guangxi[J]. Guangxi Med J，2023，45（1）：1-5.

李大双，颜建周，白铭钰，等. 抗菌药物实施国家集中带量采购的政策效果分析[J]. 中国卫生经济，2023，42（5）：17-21.

LI D S，YAN J Z，BAI M Y，et al. Analysis of the policy effect of national drug centralized procurement for antibacterial drugs[J]. Chin Health Econ，2023，42（5）：17-21.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据